The incidence of total adverse events was higher in moderate-to-severe psoriasis treated with anti-IL-23 antibody-targeted drugs than with placebo (OR = 1.66 (1.06, 2.60), P=0.03 (see Figure 6)). Here, IL37 is linked to psoriasis.